ADVERTISEMENT

Jubilant Pharmova Q2 Review - Radiopharma Business On Gradual Recovery Path: Motilal Oswal

Jubilant Pharmova Q2 Review - Radiopharma Business On Gradual Recovery Path: Motilal Oswal

<div class="paragraphs"><p>Generics medicines manufactured by Jubilant Pharmova Ltd. (Source: Company website).&nbsp;</p></div>
Generics medicines manufactured by Jubilant Pharmova Ltd. (Source: Company website). 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Jubilant Pharmova Ltd. marginally missed our Q2 FY22 earnings estimate.

The recovery in the radiopharma and allergy businesses, and sustained momentum in the contract development and manufacturing organistion business was more than offset by a decline in the generics segment.

Pricing pressure/import alert at Roorkee and industrywide issue in sartans affected the generics segment’s performance.

We have lowered our FY22E/FY23E earnings per share estimate of Jubilant Pharmova by 8.5%/4.7% to factor in:

  1. regulatory hurdles in the generics/active pharma ingredient business, and

  2. gradual recovery in the specialty business.

Click on the attachment to read the full report:

Motilal Oswal Jubilant Pharmova Q2FY22 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.